Literature DB >> 15187021

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

Masahiro Abe1, Kenji Hiura, Javier Wilde, Atsushi Shioyasono, Keiji Moriyama, Toshihiro Hashimoto, Shinsuke Kido, Takashi Oshima, Hironobu Shibata, Shuji Ozaki, Daisuke Inoue, Toshio Matsumoto.   

Abstract

Multiple myeloma (MM) expands in the bone marrow and causes devastating bone destruction by enhancing osteoclastic bone resorption in its vicinity, suggesting a close interaction between MM cells and osteoclasts (OCs). Here, we show that peripheral blood mononuclear cell-derived OCs enhanced growth and survival of primary MM cells as well as MM cell lines more potently than stromal cells, and that OCs protected MM cells from apoptosis induced by serum depletion or doxorubicin. OCs produced osteopontin (OPN) and interleukin 6 (IL-6), and adhesion of MM cells to OCs increased IL-6 production from OCs. In addition, IL-6 and OPN in combination enhanced MM cell growth and survival. However, the effects of OCs on MM cell growth and survival were only partially suppressed by a simultaneous addition of anti-IL-6 and anti-OPN antibodies and were completely abrogated by inhibition of cellular contact between MM cells and OCs. These results demonstrate that OCs enhance MM cell growth and survival through a cell-cell contact-mediated mechanism that is partially dependent on IL-6 and OPN. It is suggested that interactions of MM cells with OCs augment MM growth and survival and, thereby, form a vicious cycle, leading to extensive bone destruction and MM cell expansion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187021     DOI: 10.1182/blood-2003-11-3839

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  111 in total

1.  Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical.

Authors:  Akira Sakai; Miyo Oda; Mitsuhiro Itagaki; Noriaki Yoshida; Koji Arihiro; Akiro Kimura
Journal:  Int J Hematol       Date:  2010-10-06       Impact factor: 2.490

Review 2.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

3.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 4.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 5.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

6.  Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

Authors:  Shuji Ozaki; Osamu Tanaka; Shiro Fujii; Yuri Shigekiyo; Hirokazu Miki; Masahito Choraku; Kumiko Kagawa; Jin Asano; Kyoko Takeuchi; Ken-ichi Kitazoe; Toshihiro Hashimoto; Masahiro Abe; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

7.  Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.

Authors:  Yoichi Imai; Eri Ohta; Shu Takeda; Satoko Sunamura; Mariko Ishibashi; Hideto Tamura; Yan-Hua Wang; Atsuko Deguchi; Junji Tanaka; Yoshiro Maru; Toshiko Motoji
Journal:  JCI Insight       Date:  2016-04-21

8.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Authors:  Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; Wenlin Shao; Yung-Mae Yao; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

9.  Osteopontin increases the expression of β1, 4-galactosyltransferase-I and promotes adhesion in human RL95-2 cells.

Authors:  Feixin Zhu; Fangrong Shen; Yichao Fan; Yunpeng Xie; Ying Xia; Ying Kong
Journal:  Glycoconj J       Date:  2012-07-31       Impact factor: 2.916

10.  The ecology of cancer from an evolutionary game theory perspective.

Authors:  Jorge M Pacheco; Francisco C Santos; David Dingli
Journal:  Interface Focus       Date:  2014-08-06       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.